Bicyclic Peptide

Bicycle Therapeutics and Cancer Research UK started the first clinical study to assess a bicyclic peptide. They evaluated the possibilities in patients with advanced solid tumors.

According to Pharmatimes, the first patient was dosed in Phase I/IIa trial with BT1718, a first-in-class Bicycle Toxin Conjugate that targets Membrane Type 1 Matrix Metalloproteinase (MT1-MMP/MMP-14). This drug is reportedly familiar with the case with solid tumors. The report also revealed that the trial targets to enroll 120 patients. Rapid dose escalation will take place in the said operation and after that, an evaluation of two schedules, BT1718, will happen. BT1718 was described as the very first example of the drug conjugate technology. Its toxic chemical payloads are expressed specifically to malignant tumors as it minimizes toxin exposure through the renal clearance.

Meanwhile, partners revealed that BT1718 demonstrated “promising target-dependent efficacy in preclinical models, including both cell- and patient-derived xenografts that are resistant to treatment with standards of care.” They noted as well how the therapy is safe, showing only a subset of toxicities typically associated with other highly potent cancer treatments.

“The initiation of this study is a landmark event for the company and for our technology. We believe that Bicycles, because of their small size and exquisite selectivity, could provide meaningful efficacy to patients suffering from cancer and avoid the toxicities associated with other classes of highly potent anti-cancer drugs. We are delighted to be exploring its potential in collaboration with Cancer Research UK,” said Maria Koehler, Bicycle’s chief medical officer.

Furthermore, CR UK’s Centre for Drug Development (CDD) sponsors and co-manages the trial. Bicycle retains the right to further advance the BT1718 program under the terms of the deal. This deal is to the point of an undisclosed payment split between cash and equity, royalty payments are to be given to the charity, and success-based milestones. Still, it is worth knowing what Kroger customer want.


Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>